{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:25:17Z","timestamp":1774542317688,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen-Cilag Farmac\u00eautica Ltda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5709-y","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T13:26:14Z","timestamp":1558617974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels"],"prefix":"10.1186","volume":"19","author":[{"given":"Gustavo","family":"Werutsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Cotait","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Henrique","family":"Cronemberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Carrera Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suelen Patricia","family":"dos Santos Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Smaletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Telma","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Mavignier Carcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Queiroz Muniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo R. S.","family":"Nunes Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Facundo","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Fay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"5709_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate Cancer. JAMA Oncol. 2016;2:453\u201361.","journal-title":"JAMA Oncol"},{"key":"5709_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00345-016-1803-9","volume":"34","author":"F Rozet","year":"2016","unstructured":"Rozet F, Roumegu\u00e8re T, Spahn M, Beyersdorff D, Hammerer P. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol. 2016;34:1505\u201313.","journal-title":"World J Urol"},{"key":"5709_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","volume":"194","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate Cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537\u201347.","journal-title":"J Urol"},{"key":"5709_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","volume":"68","author":"BA Gartrell","year":"2015","unstructured":"Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, et al. Metastatic prostate Cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68:850\u20138.","journal-title":"Eur Urol"},{"key":"5709_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","volume":"50","author":"SE Barrie","year":"1994","unstructured":"Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50:267\u201373.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"5709_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"5709_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"5709_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate Cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"5709_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"5709_CR10","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/jco.2013.31.26_suppl.154","volume":"31","author":"ND James","year":"2013","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J med 2017; 377: 338\u2013351.11. Rathkopf DE, Morris MJ, fox JJ, Danila DC, Slovin SF, Hager JH, et al. phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:3525\u201330.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5709_CR11","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","volume":"28","author":"DE Rathkopf","year":"2017","unstructured":"Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:2264\u201371.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"15_suppl","key":"5709_CR12","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1200\/jco.2014.32.15_suppl.5000","volume":"32","author":"E Efstathiou","year":"2014","unstructured":"Efstathiou E, Titus MA, Wen S, SanMiguel A, Hoang A, De Haas-Amatsaleh A, et al. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32(15_suppl):5000.","journal-title":"J Clin Oncol"},{"key":"5709_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","volume":"15","author":"B Tombal","year":"2014","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15:592\u2013600.","journal-title":"Lancet Oncol"},{"key":"5709_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate Cancer. N Engl J Med. 2018;378:1408\u201318.","journal-title":"N Engl J Med"},{"key":"5709_CR15","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162). J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:3984\u201390.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5709_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1754-9485.12124","volume":"58","author":"D Chang","year":"2014","unstructured":"Chang D, Joseph DJ, Ebert MA, Galv\u00e3o DA, Taaffe DR, Denham JW, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol. 2014;58:223\u20138.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"6","key":"5709_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","volume":"50","author":"P Esper","year":"1997","unstructured":"Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997 Dec;50(6):920\u20138.","journal-title":"Urology."},{"issue":"1","key":"5709_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","volume":"12","author":"D Cella","year":"2009","unstructured":"Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of Cancer therapy--prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009 Feb;12(1):124\u20139.","journal-title":"Value Health"},{"key":"5709_CR19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.eururo.2009.06.027","volume":"56","author":"KN Chi","year":"2009","unstructured":"Chi KN, Bjartell A, Dearnaley D, Saad F, Schr\u00f6der FH, Sternberg C, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594\u2013605.","journal-title":"Eur Urol"},{"key":"5709_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","volume":"70","author":"MR Smith","year":"2016","unstructured":"Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, et al. Phase 2 study of the safety and antitumor activity of Apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate Cancer cohort. Eur Urol. 2016;70:963\u201370.","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"5709_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/jco.2013.31.6_suppl.48","volume":"31","author":"DE Rathkopf","year":"2013","unstructured":"Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, Alumkal JJ, Ryan CJ, et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(6_suppl):48.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"5709_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/JCO.2017.35.6_suppl.173","volume":"35","author":"EM Posadas","year":"2017","unstructured":"Posadas EM, Chi KN, De Wit R, De Jonge MJ, Attard G, Friedlander TW, et al. Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): update on safety and efficacy. J Clin Oncol. 2017 Feb 20;35(6_suppl):173.","journal-title":"J Clin Oncol"},{"key":"5709_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"5709_CR24","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5709-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T23:08:56Z","timestamp":1590102536000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5709-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5709-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"5 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is currently on-going in 11 sites in Brazil, all of which had study documents (final protocol, any amendments, the informed consent form, applicable recruiting materials, and subject compensation programs) approved by Institutional Ethics Committee. All study participants provided written informed consent before any study procedure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study has received funding from a commercial organization. Otherwise, the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"487"}}